CN105873576B - 治疗肥胖 - Google Patents

治疗肥胖 Download PDF

Info

Publication number
CN105873576B
CN105873576B CN201480040427.2A CN201480040427A CN105873576B CN 105873576 B CN105873576 B CN 105873576B CN 201480040427 A CN201480040427 A CN 201480040427A CN 105873576 B CN105873576 B CN 105873576B
Authority
CN
China
Prior art keywords
formulas
compound
purposes
enantiomer
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480040427.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN105873576A (zh
Inventor
M·A·哈耶拉拉
G·布里姆
S·E·巴兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Biopharmaceuticals Co Ltd
Jazz Pharmaceuticals Inc
Original Assignee
Jazz Pharmaceuticals International III Ltd
SK Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jazz Pharmaceuticals International III Ltd, SK Biopharmaceuticals Co Ltd filed Critical Jazz Pharmaceuticals International III Ltd
Priority to CN201910542872.3A priority Critical patent/CN110638804A/zh
Publication of CN105873576A publication Critical patent/CN105873576A/zh
Application granted granted Critical
Publication of CN105873576B publication Critical patent/CN105873576B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201480040427.2A 2013-07-18 2014-07-18 治疗肥胖 Active CN105873576B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910542872.3A CN110638804A (zh) 2013-07-18 2014-07-18 治疗肥胖

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361847593P 2013-07-18 2013-07-18
US61/847,593 2013-07-18
PCT/US2014/047186 WO2015010014A1 (en) 2013-07-18 2014-07-18 Treatment for obesity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910542872.3A Division CN110638804A (zh) 2013-07-18 2014-07-18 治疗肥胖

Publications (2)

Publication Number Publication Date
CN105873576A CN105873576A (zh) 2016-08-17
CN105873576B true CN105873576B (zh) 2019-07-19

Family

ID=52344067

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910542872.3A Pending CN110638804A (zh) 2013-07-18 2014-07-18 治疗肥胖
CN201480040427.2A Active CN105873576B (zh) 2013-07-18 2014-07-18 治疗肥胖

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201910542872.3A Pending CN110638804A (zh) 2013-07-18 2014-07-18 治疗肥胖

Country Status (12)

Country Link
US (6) US9226910B2 (pl)
EP (1) EP3021838B1 (pl)
JP (2) JP6529495B2 (pl)
KR (1) KR102309836B1 (pl)
CN (2) CN110638804A (pl)
CA (1) CA2917702A1 (pl)
DK (1) DK3021838T3 (pl)
ES (1) ES2812586T3 (pl)
PL (1) PL3021838T3 (pl)
PT (1) PT3021838T (pl)
TW (1) TW201919605A (pl)
WO (1) WO2015010014A1 (pl)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110638804A (zh) * 2013-07-18 2020-01-03 爵士制药国际Iii有限公司 治疗肥胖
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11839597B2 (en) 2016-07-22 2023-12-12 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI655179B (zh) * 2014-02-28 2019-04-01 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
EP3265292A1 (en) * 2015-03-02 2018-01-10 Funfare, LLC Three dimensional printer and cartridge
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
MY197630A (en) * 2016-09-06 2023-06-29 Sk Biopharmaceuticals Co Ltd Solvate form of (r)-2-amino-3-phenylpropyl carbamate
EP3523275B1 (en) 2016-10-06 2023-09-27 Axsome Malta Ltd. Carbamoyl phenylalaninol compounds for medical use
BR112019025286A2 (pt) 2017-06-02 2020-06-23 Jazz Pharmaceuticals Ireland Limited Métodos e composições para tratamento de sonolência excessiva
SG11202000817SA (en) 2017-07-31 2020-02-27 Jazz Pharmaceuticals Ireland Ltd Carbamoyl phenylalaninol analogs and uses thereof
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
EP4033068A1 (en) 2021-01-25 2022-07-27 Welltec A/S Downhole wireline tool string
WO2025006965A1 (en) 2023-06-29 2025-01-02 Axsome Therapeutics, Inc. Methods of administering solriamfetol to lactating women

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101132787A (zh) * 2004-10-28 2008-02-27 Sk株式会社 抑郁的辅助疗法
CN101217949A (zh) * 2005-06-08 2008-07-09 Sk株式会社 治疗睡眠-清醒病症
CN102481274A (zh) * 2009-06-22 2012-05-30 爱思开生物制药株式会社 治疗或预防疲劳的方法
CN102985085A (zh) * 2010-06-30 2013-03-20 爱思开生物制药株式会社 治疗双相型障碍的方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ314570A (en) 1993-06-10 2000-11-24 Lilly Co Eli Treatment of emesis using tetrahydrobenz[cd]indole-6-carboxamides
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
CA2240060C (en) 1996-10-10 2007-07-17 Sk Corporation O-carbamoyl-phenylalaninol compounds, their pharmaceutically useful salts and process for preparing the same
AU4674797A (en) 1996-10-22 1998-05-15 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
DE10148233A1 (de) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
US20040029941A1 (en) * 2002-05-06 2004-02-12 Jennings Julianne E. Zonisamide use in obesity and eating disorders
TW200507850A (en) * 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
JP5298334B2 (ja) 2005-06-22 2013-09-25 エスケー ホルディングス カンパニー リミテッド 性機能障害を治療する方法
CN101272776B (zh) 2005-07-26 2012-10-03 詹森药业有限公司 氨基甲酸酯在制备治疗物质滥用相关疾病药物中的用途
CA2673487A1 (en) 2006-10-13 2008-04-24 Janssen Pharmaceutica Nv Phenylalkylamino carbamate compositions
CA2622696A1 (en) * 2007-11-05 2009-05-05 Diane Mcintosh Methods and compositions for retarding weight gain associated with use of atypical antipsychotic drugs
WO2009129181A1 (en) * 2008-04-14 2009-10-22 Concert Pharmaceuticals Inc. Propanediol-dicarbamate derivatives
US8232315B2 (en) * 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
EP2496227B1 (en) 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
PL2496228T3 (pl) 2009-11-06 2014-06-30 Sk Biopharmaceuticals Co Ltd Sposoby leczenia zespołu nadpobudliwości psychoruchowej/deficytu uwagi
EP2543660A4 (en) * 2010-03-04 2014-04-30 Ajinomoto Kk PROPHYLACTIC OR THERAPEUTIC ACTIVE AGAINST DIABETES OR ADIPOSITAS
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
DK2968208T3 (da) 2013-03-13 2022-08-22 Jazz Pharmaceuticals Ireland Ltd Behandling af kataplexi
CA2917702A1 (en) * 2013-07-18 2015-01-22 Jazz Pharmaceuticals International Iii Limited Treatment for obesity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101132787A (zh) * 2004-10-28 2008-02-27 Sk株式会社 抑郁的辅助疗法
CN101217949A (zh) * 2005-06-08 2008-07-09 Sk株式会社 治疗睡眠-清醒病症
CN102481274A (zh) * 2009-06-22 2012-05-30 爱思开生物制药株式会社 治疗或预防疲劳的方法
CN102985085A (zh) * 2010-06-30 2013-03-20 爱思开生物制药株式会社 治疗双相型障碍的方法

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110638804A (zh) * 2013-07-18 2020-01-03 爵士制药国际Iii有限公司 治疗肥胖
US12201601B2 (en) 2013-07-18 2025-01-21 Axsome Malta Ltd. Treatment for obesity
US11497725B2 (en) 2013-07-18 2022-11-15 Axsome Malta Ltd. Treatment for obesity
US11826335B2 (en) 2016-07-22 2023-11-28 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12128021B1 (en) 2016-07-22 2024-10-29 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11766418B2 (en) 2016-07-22 2023-09-26 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12263150B2 (en) 2016-07-22 2025-04-01 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11839597B2 (en) 2016-07-22 2023-12-12 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11896572B2 (en) 2016-07-22 2024-02-13 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12138239B2 (en) 2016-07-22 2024-11-12 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12097175B2 (en) 2016-07-22 2024-09-24 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12109186B2 (en) 2016-07-22 2024-10-08 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12115145B2 (en) 2016-07-22 2024-10-15 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12115143B2 (en) 2016-07-22 2024-10-15 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12115142B2 (en) 2016-07-22 2024-10-15 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12263151B2 (en) 2016-07-22 2025-04-01 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12115144B2 (en) 2016-07-22 2024-10-15 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12097176B2 (en) 2016-07-22 2024-09-24 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12144793B2 (en) 2016-07-22 2024-11-19 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12257223B2 (en) 2016-07-22 2025-03-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12239625B2 (en) 2016-07-22 2025-03-04 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186298B2 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12226389B2 (en) 2016-07-22 2025-02-18 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12226388B2 (en) 2016-07-22 2025-02-18 Flamel Ireland Limited Modified release gamma- hydroxybutyrate formulations having improved pharmacokinetics
US12226377B2 (en) 2019-03-01 2025-02-18 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US12167992B2 (en) 2019-03-01 2024-12-17 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US12167991B2 (en) 2019-03-01 2024-12-17 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US12303478B2 (en) 2019-03-01 2025-05-20 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12295926B1 (en) 2022-02-07 2025-05-13 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Also Published As

Publication number Publication date
DK3021838T3 (da) 2020-08-24
CN110638804A (zh) 2020-01-03
KR102309836B1 (ko) 2021-10-12
WO2015010014A1 (en) 2015-01-22
US10105341B2 (en) 2018-10-23
US20210077450A1 (en) 2021-03-18
KR20160032127A (ko) 2016-03-23
US20170340596A1 (en) 2017-11-30
US9226910B2 (en) 2016-01-05
US20150025136A1 (en) 2015-01-22
EP3021838A1 (en) 2016-05-25
CN105873576A (zh) 2016-08-17
EP3021838A4 (en) 2017-01-18
JP6824315B2 (ja) 2021-02-03
PT3021838T (pt) 2020-09-01
US9649291B2 (en) 2017-05-16
US20160081970A1 (en) 2016-03-24
CA2917702A1 (en) 2015-01-22
JP6529495B2 (ja) 2019-06-12
JP2016532679A (ja) 2016-10-20
TW201919605A (zh) 2019-06-01
US12201601B2 (en) 2025-01-21
JP2019089859A (ja) 2019-06-13
US20190099395A1 (en) 2019-04-04
US20230172896A1 (en) 2023-06-08
US11497725B2 (en) 2022-11-15
PL3021838T3 (pl) 2021-03-08
ES2812586T3 (es) 2021-03-17
EP3021838B1 (en) 2020-05-27

Similar Documents

Publication Publication Date Title
CN105873576B (zh) 治疗肥胖
TWI663971B (zh) 猝倒症之治療
TWI707677B (zh) 肥胖之治療
CN110638805A (zh) 促进吸烟停止
WO2021034335A1 (en) Methods of administering tesetaxel with glucocorticoids that are cyp3a4 inducers
TW201902473A (zh) 替司他賽（ｔｅｓｅｔａｘｅｌ）及卡培他濱（ｃａｐｅｃｉｔａｂｉｎｅ）之給藥方案
AU2013368298B2 (en) Methods and compositions for administration of oxybutynin
US20230128304A1 (en) Benzimidazole compound for the treatment of metabolic disorders
HK1219236B (zh) 氨基甲酸酯化合物在製備治療猝倒的藥物中的應用
CA3116853A1 (en) Methods of treating cns tumors with tesetaxel

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20200325

Address after: Ai Erlandubailin

Co-patentee after: SK BIOPHARMACEUTICALS Co.,Ltd.

Patentee after: JAZZ PHARMACEUTICALS, Inc.

Address before: Hamilton, Bermuda

Co-patentee before: SK BIOPHARMACEUTICALS Co.,Ltd.

Patentee before: JAZZ PHARMACEUTICALS INTERNATIONAL III Ltd.

TR01 Transfer of patent right